Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

292
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
292
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

320
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
320
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

112
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
112
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

299
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
299
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

78
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
78
T Cell Types and Functions01:24

T Cell Types and Functions

1.7K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selective Senolysis of 5FU-Induced CRC Senescent Cells by Piceatannol Through Mitochondrial Depolarization and AIF-Dependent Apoptosis.

International journal of molecular sciences·2025
Same author

The endocannabinoidome-gut microbiome-brain axis as a novel therapeutic target for autism spectrum disorder.

Journal of biomedical science·2025
Same author

Neuromyelitis optica spectrum disorder in Latin America: a global data share initiative.

Multiple sclerosis and related disorders·2025
Same author

Central American and Caribbean consensus for the treatment of MS, NMOSD, and MOGAD.

Multiple sclerosis and related disorders·2025
Same author

Methods to Investigate the Secretome of Senescent Cells.

Methods and protocols·2024
Same author

Circulating microRNAs in Cancer: A 5-Year Update with a Focus on Breast and Lung Cancers.

International journal of molecular sciences·2024

Related Experiment Video

Updated: Nov 17, 2025

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

12.3K

Interferon beta 1a (Rebif®) in relapsing remitting multiple sclerosis.

Reinier Cardentey Sánchez1, Amado Díaz de la Fe1, Alejandro Peláez Suarez1

  • 1Neuromuscular Diseases Clinic, International Center for Neurological Restoration, Habana, Cuba.

Drug Development Research
|February 15, 2021
PubMed
Summary
This summary is machine-generated.

Interferon beta 1a (Rebif®) effectively treated relapsing remitting multiple sclerosis (MS). This study showed Rebif® reduced MS attacks, disability, and MRI lesions with mild side effects.

Keywords:
SRMS. Rebif®disease modifying treatmentinterferon beta 1amultiple sclerosis

More Related Videos

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.6K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.8K

Related Experiment Videos

Last Updated: Nov 17, 2025

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

12.3K
High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.6K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.8K

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is a leading cause of neurological disability in young adults.
  • It is an autoimmune neurodegenerative disease affecting the central nervous system with no known cure.
  • Evaluating novel biotechnological disease-modifying therapies is crucial for MS management.

Purpose of the Study:

  • To assess the safety and efficacy of interferon beta 1a (Rebif®) in patients with relapsing remitting MS.
  • To evaluate treatment outcomes including adverse events, disability scores, relapse rates, and MRI lesion counts.
  • To contribute clinical data on Rebif® use in a specific patient cohort.

Main Methods:

  • A prospective study involving 31 relapsing remitting MS patients (ages 10-65) treated with Rebif® for one year.
  • Treatment administered three times weekly.
  • Safety assessed via adverse events; efficacy measured by disability scale, relapse frequency, and MRI-detected lesions.

Main Results:

  • 75% of patients experienced adverse effects, predominantly mild.
  • A significant decrease in the number of relapses was observed.
  • Significant reductions in disability scale scores and new MRI lesions were noted.

Conclusions:

  • Interferon beta 1a (Rebif®) demonstrated both safety and efficacy in treating relapsing remitting MS patients.
  • The treatment led to a significant reduction in disease activity and disability.
  • Rebif® represents a viable therapeutic option for managing relapsing remitting MS.